Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Alcon AG (ALC) Price & Performance

ADMA Biologics IncTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Alcon AG — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Alcon AG trades at $72.42 (market cap $36.44B). The key difference: Alcon AG is far larger — about 16.4× ADMA Biologics Inc's market cap, and Alcon AG pays a 0.48% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAALC
Market Cap
$2.22B$36.44B
Sector
HealthHealth
52-Week High
$20.38$90.12
52-Week Low
$7.60$62.02
Enterprise Value
$2.29B$40.28B
Dividend Yield
0.48%

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC